In vivo models in mice with breast cancer-related bone metastases have shown that pharmacological sclerostin inhibition reduces metastatic burden [28], prolongs animal survival [27] and prevents cancer-related bone destruction [27,29]. Here, SOST is linked to breast carcinoma.